Jason W Bennett


Lieutenant Colonel, Army

Department of Primary Appointment:
School of Medicine
Deputy Director of Infectious Diseases
Location: Uniformed Services University of the Health Sciences, Bethesda, MD
Research Interests:
Skin and Soft Tissue Infections, MRSA
Malaria, P.vivax
Office Phone


2009 Fellowship in Infectious Diseases, Brooke Army Medical Center, San Antonio, TX
2006 Residency in Internal Medicine, Walter Reed Army Medical Center, Washington, DC
2003 MD, Medical College of Ohio, Toledo, OH
1997 MSPH (Parasitology), Tulane University School of Public Health and Tropical Medicine, New Orleans, LA
1994 BS (Biological Sciences), University of California-Irvine, Irvine, CA


Dr. Bennett is an Infectious Disease physician in the U.S. Army with extensive experience in the design and conduct of clinical trials, to include vaccine trials, and epidemiologic studies. Dr. Bennett managed the International Reference Center for Malaria Serology at WRAIR overseeing testing of clinical samples from DoD, PATH-MVI, and USAID sponsored clinical trials. He headed the U.S. military’s clinical effort testing the first P. vivax vaccine by controlled human malaria infection and was a lead clinical investigator testing other candidate malaria vaccines in the U.S. military pipeline. As the Chair of the U.S. military’s malaria vaccine Integrated Product Team he directed and prioritized the clinical development efforts for candidate vaccines within the joint U.S. Army-Navy Military Malaria Vaccine Program. He came to the Uniformed Services University and assumed the role of PI for a series of epidemiologic studies describing skin and soft tissue infections (SSTI); more specifically, his lab focuses on Staphylococcus aureus and MRSA SSTI, transmission, and colonization and among Army trainees at Fort Benning, GA. Military trainees in congregate settings are known to be at increased risk for S. aureus and MRSA colonization and infection. Knowledge gleaned from studies in this high-risk population can inform the design and implementation of clinical trials to evaluate novel medical countermeasures to reduce the high morbidity caused by this pathogen.

Representative Bibliography

Bennett, J.W., Pybus, B.S., Yadava, A., Tosh, D., Sousa, J.C., McCarthy, W.F., Deye, G., Melendez, V., and Ockenhouse, C.F. Primaquine failure and Cytochrome P-450 2D6 in Plasmodium vivax Malaria. N Engl J Med, 2013. 369(14):1381-1382

Bennett, J.W., Yadava, A., Tosh, Donna, et. al. Phase 1 Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl Trop Dis, 2016. 10(2).

Bennett, J.W., Mende, K., Herrera, M.L., Yu, X., Lewis, J.S., Wickes, B.W., Jorgensen, J.H., and C. K. Murray. Mechanisms of Carbapenem Resistance Among a Collection of Enterobacteriaceae Clinical Isolates in a Texas City. Diagnostic Microbiology and Infectious Diseases, 2010. 66(4):445-8

Millar, E.V., Rice, G.K., Elassal, E.M., Schlett, C.D., Bennett J.W., Redden, C.L., Mor D., Law, N.N., Tribble, D.R., Hamilton, T., Ellis, M.W., Bishop-Lilly, K.A. Genomic Characterization of USA300 MRSA to Evaluate Intraclass Transmission and Recurrence of SSTI among High Risk Military Trainees. Clin Infect Dis, 2017

Stahlman, S., Williams, V., Oh, G., Millar, E., and Jason W. Bennett. Skin and soft tissue infections, active component, U.S. Armed Forces, 2013–2016. Medical Surveillance Monthly Report, 2017. 24(7)